PELLEGRINI, FABIO
 Distribuzione geografica
Continente #
NA - Nord America 800
EU - Europa 89
AS - Asia 64
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 956
Nazione #
US - Stati Uniti d'America 796
CN - Cina 46
SE - Svezia 45
IT - Italia 14
GB - Regno Unito 11
FI - Finlandia 10
VN - Vietnam 10
BE - Belgio 4
HK - Hong Kong 4
CA - Canada 3
FR - Francia 3
EU - Europa 2
IL - Israele 2
UA - Ucraina 2
CR - Costa Rica 1
IN - India 1
JP - Giappone 1
PE - Perù 1
Totale 956
Città #
Fairfield 141
Woodbridge 105
Houston 75
Chandler 73
Ashburn 61
Ann Arbor 56
Seattle 55
Cambridge 51
Wilmington 43
Nyköping 36
Beijing 23
Roxbury 13
Dong Ket 10
Lawrence 10
Des Moines 9
Inglewood 8
Nanjing 8
New York 8
San Diego 8
Shenyang 7
Jacksonville 6
Brooklyn 5
Princeton 5
Bari 4
Brussels 4
Hong Kong 4
Toronto 3
Helsinki 2
Jiaxing 2
Nanchang 2
Paris 2
Taranto 2
Boardman 1
Capriate San Gervasio 1
Changsha 1
Dearborn 1
Hebei 1
Indiana 1
Jinan 1
Kilburn 1
Lima 1
London 1
Ningbo 1
Pune 1
San José 1
San Mateo 1
Tokyo 1
Totale 856
Nome #
The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial 139
Comparative efficacy of switching to natalizumab in active multiple sclerosis 97
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 90
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 85
null 85
The Intestinal Nuclear Receptor Signature With Epithelial Localization Patterns and Expression Modulation in Tumors 85
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study 80
Antiplatelet agents for chronic kidney disease 80
null 65
null 63
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting 61
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network 37
Characterization of the rs2802292 SNP identifies FOXO3A as a modifier locus predicting cancer risk in patients with PJS and PHTS hamartomatous polyposis syndromes 23
null 21
Totale 1.011
Categoria #
all - tutte 3.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.310


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019100 0 0 0 0 0 0 0 0 0 20 40 40
2019/2020324 41 9 10 41 32 19 23 32 35 30 39 13
2020/2021164 16 9 12 9 16 16 11 10 11 17 18 19
2021/2022112 10 7 0 3 9 10 4 5 7 7 18 32
2022/2023165 22 29 10 8 21 23 2 24 21 1 3 1
2023/202435 5 7 2 2 3 10 1 3 0 2 0 0
Totale 1.011